Ronald C. Chen, MD, MPH, UNC Lineberger member and associate professor in the UNC School of Medicine, was selected to represent NRG Oncology on the Prostate Cancer Task Force, a sub-committee supporting the NCI Genitourinary Cancers Steering Committee (GUSC).
Ronald C. Chen, MD, MPH, UNC Lineberger member and associate professor in the UNC School of Medicine, was selected to represent NRG Oncology on the Prostate Cancer Task Force, a sub-committee supporting the NCI Genitourinary Cancers Steering Committee (GUSC).
The appointment will be effective through November 2019.
The goal of the Genitourinary Cancers Steering Committee is to promote the best clinical and translational research for patients with genitourinary cancers, including prostate, bladder, kidney, and testicular cancer, by critically reviewing phase 2 and phase 3 clinical trial concepts.
The GUSC is assisted by three Task Forces including the Renal, Prostate and Bladder Cancers Task Forces providing advisory input to investigators early in the development of their studies for clinical trials. The ultimate goal is to create and conduct clinical trials that will have the biggest impact on the care of patients with genitourinary cancers.
The GUSC is one of seventeen steering committees formed in response to the recommendations of the Clinical Trials Working Group. These committees leverage current NCI‐supported NCTN Groups, SPORE and Consortia and involve the broad oncology community to address the design and prioritization of phase 2 and phase 3 trials on a national level.
The Prostate Task Force provides advisory input to investigators submitting their clinical trial studies to the GUSC for formal review.